{"filing":{"accession_number":"0001193125-26-342316","cik":"0001839970","ticker":null,"company_name":"BlossomHill Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d138762d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1839970/000119312526342316/d138762d8k.htm"},"events":[{"id":26501,"run_id":24088,"accession_number":"0001193125-26-342316","anchor_item_number":"8.01","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"BlossomHill Therapeutics completed its initial public offering on August 10, 2026, raising approximately $150.0 million in gross proceeds from the sale of 9,375,000 shares at $16.00 per share, fundamentally transforming the company's financial structure and investor base.","company_name":"BlossomHill Therapeutics, Inc.","ticker":null,"filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27643,"accession_number":"0001193125-26-342316","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws in connection with the IPO closing on August 10, 2026. While the IPO itself is a material event, the Item 5.03 filing addresses only the administrative governance documents (Restated Certificate and Restated Bylaws) that were previously approved by the Board and stockholders and became effective upon IPO closing. These are standard corporate governance housekeeping items that do not themselves constitute a material event to investors beyond the IPO transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:58.825345+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27644,"accession_number":"0001193125-26-342316","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BlossomHill Therapeutics completed its initial public offering on August 10, 2026, raising approximately $150.0 million in gross proceeds from the sale of 9,375,000 shares at $16.00 per share. This is a material capital-raising event that fundamentally transforms the company's financial structure and investor base. While IPOs are transformative events, they do not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution, etc.) as IPOs represent the company's transition to public markets rather than a discrete financial obligation or equity issuance within an existing public company framework. Therefore, financial_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:58.825345+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27643,"accession_number":"0001193125-26-342316","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws in connection with the IPO closing on August 10, 2026. While the IPO itself is a material event, the Item 5.03 filing addresses only the administrative governance documents (Restated Certificate and Restated Bylaws) that were previously approved by the Board and stockholders and became effective upon IPO closing. These are standard corporate governance housekeeping items that do not themselves constitute a material event to investors beyond the IPO transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:58.825345+00:00","company_name":"BlossomHill Therapeutics, Inc.","ticker":null,"filing_date":"2026-08-10"},{"id":27644,"accession_number":"0001193125-26-342316","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"BlossomHill Therapeutics completed its initial public offering on August 10, 2026, raising approximately $150.0 million in gross proceeds from the sale of 9,375,000 shares at $16.00 per share. This is a material capital-raising event that fundamentally transforms the company's financial structure and investor base. While IPOs are transformative events, they do not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution, etc.) as IPOs represent the company's transition to public markets rather than a discrete financial obligation or equity issuance within an existing public company framework. Therefore, financial_other is the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:58.825345+00:00","company_name":"BlossomHill Therapeutics, Inc.","ticker":null,"filing_date":"2026-08-10"}]}